{"id":"NCT01494467","sponsor":"Galderma R&D","briefTitle":"Phase 3 Papulopustular Rosacea Study","officialTitle":"A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2011-12-19","resultsPosted":"2015-01-16","lastUpdate":"2021-02-18"},"enrollment":688,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"CD5024","otherNames":[]},{"type":"DRUG","name":"Azelaic acid 15% Gel","otherNames":[]}],"arms":[{"label":"CD5024","type":"EXPERIMENTAL"},{"label":"CD5024 Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.","primaryOutcome":{"measure":"Success Rate","timeFrame":"Week 12","effectByArm":[{"arm":"CD5024 1% Cream","deltaMin":40.1,"sd":null},{"arm":"CD5024 Vehicle Cream","deltaMin":18.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":458},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Skin irritation"]}}